FMJ-01-38

FMJ-01-38 is a novel, highly selective dopamine D4 receptor (D4R) high-efficacy partial agonist developed by researchers at High Point University, Rowan University, and Loma Linda University. It was designed as a metabolically stable analog of the D4R agonist A-412997, utilizing click chemistry to bioisosterically replace the amide bond linker with a 1,2,3-triazole to prevent hydrolysis. In preclinical studies using spontaneously hypertensive rats (SHR/NCrl), a validated model of attention-deficit/hyperactivity disorder (ADHD), FMJ-01-38 demonstrated dose-dependent reductions in locomotor hyperactivity, improvements in attention and working memory, and decreases in impulsive choice and action. It represents a promising non-stimulant therapeutic candidate for ADHD and other neuropsychiatric disorders.